(Logo: http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO) "This approval is an important advancement for women with metastatic breast cancer, where the ...
The FDA has approved label changes for AstraZeneca‘s Faslodex (fulvestrant) injection. Labeling updates include results and a Kaplan-Meier plot of the final overall survival (OS) analysis from CONFIRM ...
FASLODEX 500 mg is indicated for the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy. FASLODEX is ...
(RTTNews) - Dr. Reddy's Laboratories Ltd. (RDY), an integrated pharmaceutical company, announced the launch of Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per single-dose syringe, a therapeutic ...
LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi announced today the immediate availability in the United States of Fulvestrant Injection 250mg per 5mL prefilled syringe, an expansion of the company ...
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today ...
(NYSE:AZN) today announced the start of a Phase III study (FALCON), a global clinical trial which will involve 450 postmenopausal patients with hormone receptor-positive locally advanced or metastatic ...
AstraZeneca announced that the FDA has approved the 500mg dose of Faslodex (fulvestrant) injection, replacing the previously approved monthly dose of 250mg, for the treatment of hormone ...
SAN ANTONIO, Texas — A double dose of fulvestrant (Faslodex, AstraZeneca) is associated with better survival than a standard dose in the treatment of postmenopausal women with advanced ...
Fresenius Kabi is offering fulvestrant injection in a 250mg per 5mL prefilled syringe. Fresenius Kabi developed its fulvestrant injection prefilled syringe to be stable at room temperature, making it ...
Pharmac has confirmed a change in the funded brand of fulvestrant injection, a medicine used to treat certain types of breast cancer. From 1 December 2025, the funded brand will change to Fulvestrant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results